David Shook

CIK: 0001959742

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (50.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

LYEL

Lyell Immunopharma, Inc.

Officer

NKTX

Nkarta, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

LYEL
Lyell Immunopharma, Inc.
Sep 10, 2026
Sale(S)
Direct
500 shares at avg. $12.70$6K
LYEL
Lyell Immunopharma, Inc.
Jun 10, 2026
Sale(S)
Direct
2K shares at avg. $12.64$25K
LYEL
Lyell Immunopharma, Inc.
Feb 10, 2026
Award(A)
Option (right to buy)
Direct
50K shares-
LYEL
Lyell Immunopharma, Inc.
Jun 9, 2025
Award(A)
Direct
21.9K shares-
NKTX
Nkarta, Inc.
Jan 15, 2025
Sale(S)
Direct
8.6K shares at avg. $2.20$19K
NKTX
Nkarta, Inc.
Jan 3, 2025
Award(A)
Direct
59K shares-

		Type	Shares	Price		Ownership
Sep 10, 2026	LYEL Lyell Immunopharma, Inc.	Sale(S)	500	$12.70	$6,350	Direct
Jun 10, 2026	LYEL Lyell Immunopharma, Inc.	Sale(S)	1,977	$12.64	$24,989	Direct
Feb 10, 2026	LYEL Lyell Immunopharma, Inc.	Award(A) Option (right to buy)	50,000	-	-	Direct
Jun 9, 2025	LYEL Lyell Immunopharma, Inc.	Award(A)	21,900	-	-	Direct
Jan 15, 2025	NKTX Nkarta, Inc.	Sale(S)	8,638	$2.20	$19,004	Direct
Jan 3, 2025	NKTX Nkarta, Inc.	Award(A)	59,000	-	$0	Direct

1-6 of 6 transactions

About Shook David

Shook David (SEC CIK 0001959742) files insider reports with the SEC as Chief Medical Officer of Lyell Immunopharma, Inc. (LYEL) and Officer of Nkarta, Inc. (NKTX).

Signal8 holds 7 ownership filings by Shook David (1 Form 3, 6 Form 4), filed between Jan 7, 2025 and Sep 10, 2026. Those filings report 6 transactions, from Jan 3, 2025 to Sep 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Shook David's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Shook David

Sep 10, 2026: Open-market sale of LYEL shares (Form 4, code S).
Jun 10, 2026: Open-market sale of LYEL shares (Form 4, code S).
Feb 10, 2026: Grant or award of LYEL derivative securities (Form 4, code A).
Jun 9, 2025: Grant or award of LYEL shares (Form 4, code A).
Jan 15, 2025: Open-market sale of NKTX shares (Form 4, code S).

Other insiders filing for Lyell Immunopharma, Inc. (LYEL)

Aguirre Jarrad Mattieu, Chief Medical Officer
Seely Lynn, President and CEO
Hill Stephen J., Chief Operating Officer
Lee Gary K., Chief Scientific Officer
Bulis Veronica Sanchez, VP, Corporate Controller
Innovative Cellular Therapeutics Holdings Ltd, 10% Owner

How to read Form 4 transaction codes